

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

image

1651

PATENT

Attorney Docket No.: 02307O-117500US

Client Reference No.: 2001-355

On September (25), 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Mark T. Davis

Mark T. Davis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wen-Lin Kuo

Application No.: 09/819,148

Filed: March 27, 2001

For: METHODS FOR DIAGNOSING
AND MONITORING MALIGNANCIES
BY SCREENING GENE COPY
NUMBERS

Examiner: Not Yet Assigned

Art Unit: 1651

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
MTD:mtd
60045416 v1



Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/819,148
		Filing Date	March 27, 2001
		First Named Inventor	Polikoff, Daniel
		Art Unit	1651
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	023070-117500US
Sheet	3	of	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	0001	Borrello et al., "trk AND ret Proto-Oncogene Expression in Human Neuroblastoma Specimens: High Frequency of trk Expression in Non-Advanced Stages", <i>Int. J. Cancer</i> 54: 540-545 (1993).	
	0002	Schneider et al., "A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trk B tyrosine kinase receptors", <i>Oncogene</i> 6: 1807-1811 (1991).	
	0003	Martin-Zanca et al., "Human mRNA of trk oncogene", <i>Database Genbank Accession No. X03541</i> (1993).	
	0004	Sato et al., "c-myc mRNA Overexpression is Associated with Lymph Node Metastasis in Colorectal Cancer", <i>Eur. J. Cancer</i> 30A:8: 1113-1117 (1994).	
	0005	Lemoine et al., "The Epidermal Growth Factor Receptor in Human Pancreatic Cancer", <i>Journal of Pathology</i> 166:7: 7-12 (1992).	
	0006	Scorilas et al., "Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis", <i>British Journal of Cancer</i> 81:8: 1385-1391 (1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.